A [C-11]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT-555 on Central Nervous System Inflammation in Subjects With Relapsing Forms of Multiple Sclerosis
Phase of Trial: Phase I
Latest Information Update: 10 Feb 2017
At a glance
- Drugs ABT 555 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors AbbVie
- 06 Feb 2017 Status changed from suspended to discontinued.
- 18 Oct 2016 Planned End Date changed from 1 Apr 2017 to 1 Aug 2017.
- 18 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Aug 2017.